ASSURE Wearable ECG vs Zio XT ECG Monitoring System
AI Verdict
Choose ASSURE Wearable ECG if…
Choose ASSURE Wearable ECG if your patients require continuous, multi-channel heart rate monitoring with advanced artifact filtering, particularly for at-risk cardiac patients needing ongoing oversight. Its integrated digital healthcare platform and Kestra CareStation provide comprehensive clinician review of physiologic trend data and alert-based notifications for proactive management.
View ASSURE Wearable ECG →Choose Zio XT ECG Monitoring System if…
Choose Zio XT ECG Monitoring System if you need a convenient, short-term diagnostic solution for suspected arrhythmias, offering up to 14 days of continuous monitoring. Its water-resistant, wire-free design promotes high patient compliance and comfort, while FDA-cleared AI and expert review provide accurate arrhythmia detection for diagnostic purposes.
View Zio XT ECG Monitoring System →For physicians evaluating cardiac monitoring solutions, the ASSURE Wearable ECG and Zio XT ECG Monitoring System offer distinct advantages. The ASSURE Wearable ECG, from Kestra Medical Technologies, excels in continuous, multi-channel heart rate monitoring and data collection, integrated into a comprehensive digital healthcare platform. Its key features include a SensorFit Garment with cushioned ECG sensors, the Quad Channel Processing™ ASSURE Detection Algorithm, and Adaptive Patient Intelligence™ for motion artifact filtering. This system is best suited for at-risk cardiac patients requiring detailed, ongoing physiologic trend data and alert-based notifications, with clinician review facilitated through the Kestra CareStation remote patient data platform.
In contrast, the Zio XT ECG Monitoring System by iRhythm Technologies provides a wearable, single-lead ECG biosensor for up to 14 days of continuous ambulatory monitoring. Its strength lies in its simplicity, high patient compliance, and FDA-cleared deep-learned AI algorithm for accurate arrhythmia detection and diagnosis, complemented by expert review. The practical difference is that ASSURE offers a multi-channel approach with advanced artifact filtering for potentially more granular data, while Zio XT prioritizes ease of use, extended wear time, and a streamlined diagnostic pathway with its proprietary AI and expert analysis. Physicians prioritizing comprehensive, multi-channel data and a robust digital platform for complex cardiac patients may lean towards ASSURE. Those seeking a highly compliant, user-friendly, and efficient solution for arrhythmia detection over an extended period, particularly across cardiology, emergency medicine, and internal medicine, would likely find Zio XT more appropriate.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ASSURE Wearable ECG | Zio XT ECG Monitoring System |
|---|---|---|
| Pricing | Contact for pricing. | Contact for pricing |
| Deployment | Wearable device, mobile application, and cloud-based remote patient data platform. | Cloud-based (AWS EC2 platform), no on-premise hardware required. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio XT ECG Monitoring SystemTool B emphasizes features like a water-resistant design and the absence of external leads or wires, which significantly enhance patient comfort and allow for normal daily activities, including showering. Its reported high patient compliance (up to 99%) and satisfaction further demonstrate superior real-world usability.
Clinical Value
Zio XT ECG Monitoring SystemBoth tools are FDA-cleared and offer continuous monitoring with AI analysis. However, Tool B provides up to 14 days of continuous monitoring, which is a longer duration than many standard monitors and can be crucial for detecting intermittent arrhythmias. Its combination of an FDA-cleared deep-learned AI algorithm with expert review and a patient-activated button for symptomatic event logging offers a comprehensive and diagnostically rich solution.
Pricing & Value
Zio XT ECG Monitoring SystemTool B provides specific pricing examples for both the UK (u00a3310 per patient) and proposed US Medicare rates ($229-$260.35), offering a clear indication of potential costs and allowing for a preliminary value assessment. In contrast, Tool A offers no public pricing information, making it impossible to evaluate its pricing or value proposition without direct contact.
Enterprise Readiness
Zio XT ECG Monitoring SystemBoth tools meet critical enterprise requirements like HIPAA compliance, BAA, and FDA clearance, and leverage cloud platforms. However, Tool B explicitly states 'no on-premise hardware required' and specifies deployment on the 'AWS EC2 platform,' suggesting a potentially simpler and more scalable integration for large healthcare systems without the need for managing local infrastructure.
Innovation
TieBoth tools demonstrate significant innovation in cardiac monitoring. Tool A's 'Quad Channel Processing' and 'Adaptive Patient Intelligence' for artifact filtering represent advanced data acquisition and processing. Tool B's proprietary 'deep-learned AI algorithm,' combined with its wire-free, water-resistant design for extended 14-day monitoring, also pushes boundaries in patient comfort and diagnostic duration.
Support & Docs
Zio XT ECG Monitoring SystemWhile the initial JSON provided limited details for both, web searches indicate that iRhythm (Tool B) offers more visible and structured resources for healthcare professionals, including clinician guides, patient FAQs, and a dedicated support section on its website, with a 24/7/365 billing team. Kestra Medical Technologies (Tool A) also provides an ASSURE Helpline and patient handbook, and in-person training, but the breadth of publicly available, structured support resources appears more extensive for Tool B.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ASSURE Wearable ECG | Zio XT ECG Monitoring System |
|---|---|---|
| Primary Use Case | Non-therapeutic device for continuous heart rate monitoring and data collection for at-risk cardiac patients. | Wearable, single-lead ECG biosensor for continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis. |
| Monitoring Duration | Continuous heart rate monitoring (specific duration not specified). | Up to 14 days of continuous cardiac monitoring. |
| Sensor Technology | SensorFit Garment with non-adhesive, embedded, and cushioned ECG sensors. | Wearable single-lead ECG biosensor (Zio biosensor), no external leads or wires, water-resistant design. |
| AI/Algorithm Capabilities | ASSURE Detection Algorithm with Quad Channel Processingu2122, Adaptive Patient Intelligenceu2122 for filtering motion artifacts. | Proprietary, FDA-cleared deep-learned AI algorithm for ECG data analysis. |
| Data Platform | Kestra CareStation remote patient data platform. | Cloud-based software platform (ZEUS) for data storage, analysis, and reporting. |
| Patient-Facing Features | Wearable ECG device, SensorFit Garment. | Water-resistant design for normal daily activities, including showering; no external leads or wires; patient-activated button for symptomatic event logging. |
| Clinician-Facing Features | Automatic episode storage, alert-based notifications, physiologic trend data, Kestra CareStation for clinician review. | Cloud-based software platform (ZEUS) for data storage, analysis, and reporting; expert review. |
Videos
Demos, reviews, and walkthroughs featuring ASSURE Wearable ECG and Zio XT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring ASSURE Wearable ECG or Zio XT ECG Monitoring System
Backers
Who funded each tool's parent company.